Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company''s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company''s early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Latest shares articles
GBP drops as BOE vote split seems dovish
The BOE has left rates unchanged in December but a more dovish vote split has weighed on the pound.
13:15, 19 December 2024
A hawkish Fed cut sparks fresh volatility
Discover how the Federal Reserve's hawkish stance, revised SEP, and delayed inflation targets triggered market volatility, with stocks tumbling, bond yields surging, and a stronger US Dollar reshaping investor outlooks.
12:46, 19 December 2024
Gold Latest: XAU/USD stuck within range ahead of the FOMC meeting
Gold traders await the FOMC meeting to determine how many rate cuts to expect in 2025.
11:25, 18 December 2024
GBP/USD in focus ahead of FED and BOE meetings
Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
17:33, 17 December 2024
Ratings and Reviews
Ratings and Reviews
